EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Long‐Term Five‐Year Effectiveness of Tenofovir Alafenamide in Japanese Patients With Chronic Hepatitis B: A Prospective Multicenter Registry Study

Hitomi Takada, Nobuharu Tamaki, Hironori Ochi, Hiroyuki Marusawa, Masahiko Kondo, Naofumi Urawa, Yasushi Uchida, Hideo Yoshida, Eisuke Okamoto, Hideki Fujii, Junichi Toshimori, Takehiro Akahane und 2 weitere

JGH Open · 2026-11 · 10 (11)

DOI: 10.1002/jgh3.70502 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JGH Open, online erschienen am 16.11.2026. Verfasst von Hitomi Takada und 13 weiteren Autor:innen. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Health, Labour and Welfare, Japan Agency for Medical Research and Development.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Aims Tenofovir alafenamide (TAF) is recommended as a first‐line therapy for chronic hepatitis B (CHB); however, long‐term real‐world data in Japan are limited. This study aimed to evaluate the 5‐year efficacy of TAF in a multicenter cohort.

Methods

This prospective multicenter registry study included 638 patients with CHB who initiated TAF therapy between March 2019 and March 2025. The primary outcomes were the HBV‐DNA suppression rate and alanine aminotransferase (ALT) normalization rate at 5 years. Subgroup analyses were performed according to treatment history, disease stage, and renal function.

Results

The HBV‐DNA suppression rate increased over time and reached 97% at 5 years. Comparable suppression rates were observed between treatment‐naïve patients and patients switched from other nucleos(t)ide analogues (NAs) to TAF (97% vs. 97%, p = 1.0), as well as between patients with chronic hepatitis and those with liver cirrhosis (97% vs. 100%, p = 0.60). The overall ALT normalization rate at 5 years was 84%. Among patients switched from other NAs to TAF with detectable HBV‐DNA at baseline, 87% achieved viral suppression. In patients with renal impairment (eGFR < 60 mL/min/1.73 m 2 ), the suppression rate was 97%, comparable to those with normal renal function (97%, p = 1.0).

Conclusion

TAF demonstrated sustained and high antiviral efficacy over 5 years in a real‐world Japanese cohort, including in patients switched from other nucleos(t)ide analogues and those with renal impairment. These findings support the long‐term effectiveness of TAF across a broad spectrum of patients with CHB in routine clinical practice.

Förderung

  • Ministry of Health, Labour and Welfare
  • Japan Agency for Medical Research and Development

Zitieren

APA

Takada, H., Tamaki, N., Ochi, H., Marusawa, H., Kondo, M., Urawa, N., Uchida, Y., Yoshida, H., Okamoto, E., Fujii, H., Toshimori, J., Akahane, T., Ishii, T., & Kurosaki, M. (2026). Long‐Term Five‐Year Effectiveness of Tenofovir Alafenamide in Japanese Patients With Chronic Hepatitis B: A Prospective Multicenter Registry Study. JGH Open, 10(11). https://doi.org/10.1002/jgh3.70502

Vancouver

Takada H, Tamaki N, Ochi H, Marusawa H, Kondo M, Urawa N, et al. Long‐Term Five‐Year Effectiveness of Tenofovir Alafenamide in Japanese Patients With Chronic Hepatitis B: A Prospective Multicenter Registry Study. JGH Open. 2026;10(11). doi:10.1002/jgh3.70502

BibTeX
@article{Takada2026,
  author = {Takada, Hitomi and Tamaki, Nobuharu and Ochi, Hironori and Marusawa, Hiroyuki and Kondo, Masahiko and Urawa, Naofumi and Uchida, Yasushi and Yoshida, Hideo and Okamoto, Eisuke and Fujii, Hideki and Toshimori, Junichi and Akahane, Takehiro and Ishii, Toru and Kurosaki, Masayuki},
  title = {Long‐Term Five‐Year Effectiveness of Tenofovir Alafenamide in Japanese Patients With Chronic Hepatitis B: A Prospective Multicenter Registry Study},
  journal = {JGH Open},
  year = {2026},
  volume = {10},
  number = {11},
  doi = {10.1002/jgh3.70502}
}
Kostenlos starten →